16 Feb 2021

We still see significant long-term value

Aker BioMarine ASA (AKBM:OSL) | 0 0 0.0%

- Thomas Lorck | Axel Jacobsen
- 15 pages

Aker BioMarine’s Q4/20 results fell slightly short of our expectations, and we have lowered our 2021-2022 adj. EBITDA by 6% and 7% respectively after implementing the updated guiding. Management reiterates its 2024 adj. EBITDA target of USD 200m, and one should note that the recent announcements of Lysoveta, AION and INVI will come on top of this target. We still see significant long-term value, and reiterate our Buy rating and NOK 185 TP.

Sign up to access

Get access to our full offering from over 100 providers

We still see significant long-term value

Aker BioMarine ASA (AKBM:OSL) | 0 0 0.0%

Published: 16 Feb 2021
Author: Thomas Lorck | Axel Jacobsen
Pages: 15

Aker BioMarine’s Q4/20 results fell slightly short of our expectations, and we have lowered our 2021-2022 adj. EBITDA by 6% and 7% respectively after implementing the updated guiding. Management reiterates its 2024 adj. EBITDA target of USD 200m, and one should note that the recent announcements of Lysoveta, AION and INVI will come on top of this target. We still see significant long-term value, and reiterate our Buy rating and NOK 185 TP.